Table 1.
Selected neuraminidase mutations conferring resistance to neuraminidase inhibitors (mainly reviewed in52)
| Influenza subtype | NA mutation | Virus source / NAI used for selection | Phenotype in NA inhibition assaysa | ||
|---|---|---|---|---|---|
| Oseltamivir | Zanamivir | Peramivir | |||
| A(H1N1) | H275Y | Clinic / Oseltamivir | HRI | S | HRI |
| Q136K | In vitro (clinic?) / None | S | HRI | RI | |
| A(H1N1)pdm09 | N295S | Reverse Genetics | HRI | S | RI |
| H275Y | Clinic / Oseltamivir | HRI | S | RI | |
| S247N/H275Y | Clinic / None | HRI | S | RI | |
| I223V/H275Y | Clinic / Oseltamivir | HRI | S | ‐ | |
| Reverse Genetics | HRI | S | HRI | ||
| I223R/H275Y | Clinic / Oseltamivir | HRI | RI | HRI | |
| Reverse Genetics | HRI | RI | HRI | ||
| I223R | Clinic / Oseltamivir | RI | RI | ‐ | |
| Reverse Genetics | RI | RI | RI | ||
| E119G | Reverse Genetics | S | HRI | RI | |
| E119V | Reverse Genetics | RI | HRI | RI | |
| A(H5N1) | N295S | Clinic / Oseltamivir | RI | S | S |
| H275Y | Clinic / Oseltamivir | HRI | S | HRI | |
| D199G | In vitro / Zanamivir | RI | RI | S | |
| E119G | In vitro / Zanamivir | S | HRI | RI/HRI | |
| A(H3N2) | N294S | Clinic / Oseltamivir | HRI | S | ‐ |
| R292K | Clinic / Oseltamivir | HRI | ‐ | ‐ | |
| Reverse Genetics | HRI | S/RI | RI | ||
| Deletion 245–248 | Clinic / Oseltamivir | HRI | S | S | |
| D151A/D | Clinic?/ None | S | HRI | ‐ | |
| Q136K | Clinic?/ None | S | RI | ‐ | |
| E119V/I222V | Clinic / Oseltamivir | HRI | S | S | |
| E119V | Clinic / Oseltamivir | HRI | S | S | |
| B | R371K | Clinic/ None | HRI | RI | ‐ |
| N294S | Clinic/ None | HRI | ‐ | ‐ | |
| R292K | Reverse Genetics | S | RI | HRI | |
| H273Y | Clinic? / ? | RI | S | RI | |
| D197N | Clinic / Oseltamivir | RI | RI | RI | |
| R150K | Clinic / Zanamivir | HRI | RI | HRI | |
| Reverse Genetics | HRI | RI | HRI | ||
| E116A | Reverse Genetics | HRI | HRI | HRI | |
| E116D | Reverse Genetics | HRI | HRI | HRI | |
| E116G | Reverse Genetics | RI | HRI | HRI | |
| E116V | Reverse Genetics | HRI | S | HRI | |
| E105K | Clinical / None | S | RI | HRI | |
a
S, susceptibility or normal inhibition (<10‐fold increase in IC50 over WT for A viruses or <5‐fold increase for B viruses); RI, reduced inhibition (10‐ to 100‐fold increase in IC50 over WT for A viruses or 5‐ to 50‐fold increase for B viruses); HRI, highly reduced inhibition (>100‐fold increase in IC50 over WT for A viruses or >50‐fold increase for B viruses). ? means uncertain or unknown information.